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Abstract 3 
Objective: Glucocorticoid usage, a leading cause of osteonecrosis of the femoral head (ONFH), and its 4 
prevalence was reported in 25-50% of non-traumatic ONFH patients. Nevertheless, there have been no 5 
unified criteria to classify glucocorticoid-associated ONFH (GA-ONFH). In 2015, the Association 6 
Research Circulation Osseous (ARCO) addressed the issue of developing a classification scheme. 7 
Methods: In June 2017, a task force was set up to conduct a Delphi survey concerning ONFH. The task 8 
force invited twenty-eight experts in osteonecrosis/bone circulation from eight countries. Each round of 9 
the Delphi survey consists of questionnaires, analysis of replies and feedback reports to the panel. After 10 
three rounds of the survey, the panel reached a consensus on the classification criteria. The response rates 11 
were 100% (round 1), 96% (rounds 2) and 100% (round 3), respectively. 12 
Results: The consensus on the classification criteria of GA-ONFH included: 1) patients should have a 13 
history of glucocorticoid use > 2g of prednisolone or its equivalent within a 3-month period; 2) 14 
osteonecrosis should be diagnosed within two years after glucocorticoid usage, and 3) patients should not 15 
have other risk factor(s) besides glucocorticoids.  16 
Conclusion: ARCO established classification criteria to standardize clinical studies concerning GA-17 
ONFH.  18 
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Introduction 21 
Osteonecrosis of the femoral head (ONFH) is a potentially devastating disease frequently leading to 22 
collapse of the femoral head and osteoarthritis of the hip.[1, 2] Specifically, non-traumatic ONFH usually 23 
affects young and middle-aged adults and the prevalence has been reported to be increasing.[3, 4] 24 
Although non-traumatic ONFH is the final common manifestation of various diseases or conditions 25 
compromising the local circulation in the femoral head, the pathogenic mechanisms are multifactorial and 26 
have yet to be fully elucidated.[5]  27 
 Among non-traumatic ONFH cases, glucocorticoids have been identified as the leading cause and 28 
reportedly contributed to its development in 25-50% of patients.[3, 6-8] These agents have been used as a 29 
first-line anti-inflammatory and immune-modulating drug for many immune-mediated conditions or as an 30 
adjunctive therapy for some infectious or malignant diseases. Prospective studies using magnetic 31 
resonance imaging (MRI) have reported that glucocorticoid-associated ONFH (GA-ONFH) was detected 32 
in 15 to 35% of patients with systemic lupus erythematous.[9] The susceptibility to GA-ONFH has been 33 
considered dependent on multiple factors including genetic background, the duration or amount of 34 
glucocorticoids exposure, and underlying diseases.[10, 11] Thus, it is difficult to determine the risk dose 35 
or duration of glucocorticoids to develop ONFH and previously, most researchers could not avoid using 36 
their own definitions or criteria for corticosteroid-associated ONFH. As a result, because of 37 
inhomogeneity within the GA-ONFH populations studied, it is difficult to compare the results across the 38 
studies and to collect data enough to augment our understanding of patients with this association. 39 
 The Association Research Circulation Osseous (ARCO) founded in 1973 has been the only international 40 
society promoting the study of bone circulation and its disorders in particular of osteonecrosis. In April 41 
2015, ARCO addressed some of these issues on classification criteria of non-traumatic ONFH and formed 42 
a task force to establishing the criteria for GA-ONFH and alcohol-associated osteonecrosis. Because of 43 
the lack of sufficient scientific evidence in the literature, the task force decided to employ a modified, 44 
consensus-building Delphi method, by gathering data from experts using rounds of questionnaires.  45 
Since the present study aimed to develop the classification criteria for GA-ONFH to identify a well-46 
defined homogenous population for research, our criteria should not be misinterpreted as diagnostic 47 
criteria for clinical practice. 48 
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Methods 49 
ARCO task force 50 
The ARCO task force was set up to prepare the Delphi survey and consisted of 7 members; 4 orthopaedic 51 
surgeons, 1 expert researcher on bone circulation/osteonecrosis, 1 rheumatologist and 1 52 
statistician/methodologist. The task force performed a search of PubMed, using the key search terms 53 
“osteonecrosis”, “avascular necrosis”, “aseptic necrosis”, “glucocorticoid”, and “steroid” for entries from 54 
January 1, 1960, to May 31, 2017. The search was restricted to human studies in the over 18 years’ age 55 
group. The task force reviewed 75 citations relevant to GA-ONFH and selected 23 key literatures 56 
(Supplementary 1). Through the comprehensive literature review, the task force raised 4 issues to develop 57 
novel etiologic classification criteria of GA-ONFH; 1) whether experts necessitate classification criteria 58 
of GA-ONFH, 2) minimal dosage of glucocorticoids that need to have been administered to the patients; 59 
3) the latent period after exposure to glucocorticoid, when a diagnosis of ONFH can be made; 4) how to 60 
classify ONFH patients, who have other risk factor(s) besides glucocorticoid. 61 
Expert panel members 62 
 In June of 2017, the task force initially invited 30 experts because the sample size of a panel has usually 63 
been recommended to 15 to 30 participants in the Delphi study design and a larger sample size (beyond 64 
30) has rarely found to improve the results.[12] ARCO made the panel qualifications for the Delphi study; 65 
college faculty, more than 10 years of clinical and/or research experience, and 3 or more publications on 66 
bone circulation/osteonecrosis, for a homogeneous panel based on the knowledge on ONFH and level of 67 
clinical or research experience. Among the 30 experts, one declined the invitation and one did not reply to 68 
the invitation. The remaining 28 experts on osteonecrosis/bone circulation participated in the Delphi 69 
procedure (Table 1). The panel members had a mean of approximately 18 years of clinical and/or research 70 
experience. 71 
 The modified Delphi procedure  72 
The Delphi technique is a widely accepted method for achieving convergence of expert opinions. The 73 
following features characterize the procedures: anonymity, iteration, and controlled feedback. Anonymity 74 
allows participants to express their opinions freely without being pressured by other participants, and 75 
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permits them to change their opinion if necessary, thus helping participants consider the issues based on 76 
merits alone. In this study, anonymity was achieved by an Internet survey. Iteration is achieved by 77 
presenting questionnaires several times over a number of rounds, thereby allowing participants to change 78 
their opinions. Controlled feedback takes place between rounds: each participant learns of the other 79 
participants’ opinions. Participants often receive this feedback as a simple statistical summary of 80 
responses, although arguments may present. This ensures that all of the participants contribute to the 81 
discussion. 82 
Construction of Delphi rounds 83 
 A total three or four rounds was expected to reach consensus on the 4 issues, which were raised by the 84 
ARCO task force. In the first survey, the panel members were asked to answer 4 open-ended questions on 85 
the 4 issues; 1) whether etiologic classification criteria for glucocorticoid are necessary and their reasons 86 
why; 2) their own criteria to classify osteonecrosis as GA-ONFH in terms of cumulative dose of 87 
prednisolone or its equivalent; 3) the duration of the effects of lasting risk exposure (latent period – time 88 
from the past exposure to diagnosis of ONFH); and 4) how to classify ONFH patients who have 2 or 89 
more risk factors including glucocorticoid therapy. 90 
Replies to the first survey were analyzed to determine whether consensus was reached or not.  91 
In the second and further rounds, the panel members were asked to answer the revised questionnaires on 92 
the issues, on which the panel members did not reach consensus in the previous round. The rounds were 93 
continued until final consensus was obtained on the 4 issues. 94 
Cut-off point for consensus 95 
The content validity ratio (CVR) is a linear transformation of a proportional level of agreement.[13] The 96 
main benefit of CVR is to readily indicate whether the level of agreement among panel members exceeds 97 
50%. It represents the proportion of panel participants, who rate an item as essential, and is calculated as 98 
follows:  99 
 NE – (N/2)        NE is the number of panel members rating the item as essential  100 
   N/2                 N is the number of panel members. 101 
 We had 28 panel members; therefore, the cut off value of CVR was 0.357, which means 19 is a 102 
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minimum number of panels required to reach a consensus in each questionnaire. 103 
Data synthesis and analysis 104 
Data from all Delphi rounds were extracted from the online survey database to an Excel V.20.0 105 
spreadsheet, and anonymously reported as feedback to each panelist. Qualitative data (i.e., expert answers 106 
and justifications) were analyzed by content analysis and discussed by the task force.  In the first open-107 
ended round, the replies were integrated and classified according to the frequency analysis. In the second 108 
and further rounds consisting of multiple choice questions, the percentage and CVR of answers in each 109 
item were calculated.  110 
Source of Funding 111 
No external funding was received in support of this work and ARCO. 112 
Results 113 
 Three consecutive Delphi rounds were performed between July 1, 2017 and October 31, 2017. Through 114 
the three Delphi rounds, full consensus was reached on the classification criteria of GA-ONFH. 115 
Round 1: Open round 116 
Four questionnaires were sent to the panel members (Table 2) and the response rate was 100%. 117 
 From the replies to the first Delphi survey, consensus was reached on one issue (questionnaire 1) about 118 
the necessity of the classification criteria. Twenty-three panel members (82.1%) agreed the necessity of 119 
classification criteria, whereas, five members (17.9%) disagreed. The most common reason for the 120 
agreement was that although glucocorticoid is the most common associated risk factor for ONFH, there 121 
are no defined classification criteria.  122 
Predictably, consensus was not reached on the remaining three issues of cumulative dose of 123 
glucocorticoids, latent periods, as well as how to classify patients with multiple risk factors (Table 2). 124 
Several panel members also suggested changing the term “glucocorticoid-induced” to “glucocorticoid-125 
associated” because the exact causal relationship between glucocorticoid and the development of ONFH 126 
has not been determined yet. 127 
Round 2: Selecting and limiting round with multiple choice questions 128 
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Questionnaires on the three issues, on which consensus was not reached in Round 1, were modified to 129 
multiple-choice questions in order to promote convergence of the various replies. Four multiple-choice 130 
questionnaires were compiled using lists of categories and panelists were asked to select the most 131 
appropriate category. The issue of terminology change from “glucocorticoid-induced” to “glucocorticoid-132 
associated” was also included in Round 2. 133 
The response rate was 96% in Round 2. Consensus was reached on two issues: the classification of 134 
patients with multiple risk factors and the term issue. However, consensus was not reached on the two 135 
issues of risk dose and latent period (Table 3). 136 
Round 3: Ranking round  137 
  To promote convergence of replies on the two unresolved issues in Round 2, the panel members were 138 
given the opportunity to state whether or not they agreed with the category showing the highest response 139 
frequency in Round 2 and to re-enter their rationale or reason why they did not agree. This was to ensure 140 
that the respondents had the opportunity to state whether or not they agreed with the category showing the 141 
highest response frequency in round 2. The response rate was 100% in Round 3 and since consensus was 142 
reached on the remaining two queries, the classification criteria for GA-ONFH were completed (Table 4). 143 
Final consensus 144 
To classify an ONFH patient as a GA-ONFH patient: 1) subjects should have a history of glucocorticoid 145 
use > 2 grams of prednisolone or its equivalent within a 3 month duration; 2) ONFH should be diagnosed 146 
within two years after this glucocorticoid dosage; and 3) patients should not have other risk factor(s) than 147 
glucocorticoids (Table 5). 148 
Approval of the consensus 149 
 The results of the Delphi study and the final consensus on the classification criteria of GA-ONFH were 150 
presented (Table 5) and approved in the general meeting of ARCO, which was held in October 25, 2017 151 
in Berlin. 152 
Discussion 153 
Glucocorticoid usage has been a leading cause of non-traumatic ONFH. In addition, this risk factor may 154 
be a second insult added in patients with severe diseases requiring high dose long-term glucocorticoid 155 
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therapy.[14] GA-ONFH can develop within several weeks after starting high dose glucocorticoid 156 
treatment in many patients.[15] Most patients that gave large-to-moderate asymptomatic ONFH lesions 157 
frequently progress to need surgical treatment.[16] However, we cannot predict GA-ONFH development 158 
in each patient with glucocorticoid therapy because GA-ONFH has a multifactorial etiology. 159 
Some glucocorticoid users with genetic predispositions have a greater susceptibility for developing 160 
ONFH, while other users without genetic predispositions may not develop the disease.[17-20] It is not 161 
possible to define the risk dose of glucocorticoids to develop ONFH. Nevertheless, previous studies have 162 
shown that there is a strong association between ONFH development and higher doses of glucocorticoid.  163 
In a quantitative review of 22 studies with sufficient information, a strong correlation was found between 164 
daily total dose and the rate of ONFH (r = 0.61-0.80). The rate of the disease increased by 4.6 % in 165 
accordance with every 10 mg increase in daily dose of glucocorticoid.[21] In a prospective MRI study in 166 
302 patients who required glucocorticoid therapy due to SLE or other rheumatological disorders, the 167 
incidence of ONFH at 1 year was 37% in SLE patients and 21% in non-SLE patients. High daily dose of 168 
glucocorticoid (>40 mg/day) entailed a higher risk of ONFH compared with a daily dose of 169 
glucocorticoid <40 mg/day (OR = 4.2).[22] Another prospective MRI study of 286 patients undergoing 170 
renal transplantation investigated the risk of ONFH at a very early stage after transplantation. According 171 
to the total doses of glucocorticoid use in the first 2 weeks postoperatively, patients were classified as 172 
lower (≤ 520 mg), middle (520–600 mg), and higher (> 600 mg) tertiles. The incidence of ONFH was 6% 173 
in the lower-dose group, 17% in the middle-dose group, and 28% in the higher-dose group.[23] Thus, we 174 
included the dose of glucocorticoids as a criterion in the present classification criteria for GA-ONFH; the 175 
experts reached a consensus that subjects should receive a cumulative dose of 2 g or more over less than 3 176 
months. In fact, such criteria about the dose and administration duration were deduced from the previous 177 
studies performed in adult patients with several diseases including SLE and renal transplantation. But, 178 
glucocorticoids are introduced for the treatment of a variety of inflammatory, immunologic, or neoplastic 179 
conditions. In a recent large population-based study, although underlying disease conditions were 180 
statistically independently associated with ONFH, a similar dose relationship was found between 181 
glucocorticoids and ONFH among adults with low-risk and high-risk diseases.[24] Therefore, we 182 
recommend to apply the criteria regardless of underlying diseases.  183 
  A previous study suggested that there is a risk period for developing ONFH in glucocorticoid users.[25] 184 
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In two prospective studies, ONFH developed within 3 to 12 months after the initiation of glucocorticoid 185 
treatment,[15, 23] by tracking serial MRIs in every patient regardless of symptoms. The natural history of 186 
ONFH has been well- investigated. About one-third of patients with asymptomatic early GA-ONFH have 187 
symptomatic or radiological progression over a period of several months to years.[26] Practically, there is 188 
a time lag between the ONFH development and the diagnosis of the disease. The diagnosis is often 189 
delayed because work-up is made when patients have pain and MRI are not always utilized. Zhao et al. 190 
reported that the median period from glucocorticoid therapy to hip pain was 18 months in 269 patients 191 
with GA-ONFH and that 67% complained of hip symptoms within 24 months after commencing 192 
glucocorticoids.[27] Therefore, we discussed the issue of the time lag from the discontinuation of 193 
glucocorticoids to ONFH diagnosis, and finally reached consensus that cases should be excluded if they 194 
are diagnosed with non-traumatic ONFH after the discontinuation of glucocorticoids, in spite of past 195 
exposure history to high dose glucocorticoid therapy.  196 
In addition, to obtain as high a degree of homogeneity as possible, we assessed cases with 2 or more 197 
associated risk factors. For example, in the study of Ikeuchi et al., the researchers classified patients with 198 
non-traumatic ONFH according to risk factors and about 5% were both corticosteroid- and alcohol- 199 
associated ONFH.[28] Our experts recommended not to classify the cases into GA-ONFH if they have 200 
another possible cause other than high-dose glucocorticoids including trauma, alcohol overuse, hereditary 201 
coagulopathies, Caisson disease, radiation therapy involving the femoral head, non-glucocorticoid 202 
chemotherapeutics for cancer, or Gaucher’s disease. 203 
 The current criteria should not be used as diagnostic criteria for GA-ONFH in clinical practice or are not 204 
suitable for reference in a medicolegal issue. Classification criteria are standardized definitions to create 205 
homogenous cohorts for clinical research, while diagnostic criteria are developed to reach an accurate 206 
diagnosis. 207 
 The Delphi consensus method has low external validity in terms of scientific evidence. However, this 208 
method is valuable in situations where imprecise or contradictory opinions exist.[29] Because of the 209 
multifactorial nature, it is difficult to define this disease. Until now, we have no established classification 210 
criteria for GA-ONFH and previous studies applied their own criteria or definitions, often without clear 211 
underlying evidence. Many different definitions have hindered us from understanding of the disease as a 212 
whole or acquiring new knowledge by collecting and analyzing the published data. In such a context, 213 
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ARCO believes that the present criteria for GA-ONFH can define a homogeneous group of subjects, and 214 
facilitate performance of studies concerning various ethnic populations or by different researchers. 215 
However, this study did not provide the validity and reliability of the criteria. Therefore, at the further 216 
study, the classification criteria should be tested by comparison with clinical diagnosis made by 217 
physicians and in multicenter or multiethnic large cohorts. 218 
Conclusion  219 
The current Delphi survey provides etiologic classification criteria of GA-ONFH. ARCO recommends 220 
using the criteria for studies about ONFH. 221 
Disclosure statement  The authors declare no conflict of interest.  222 
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Supplementary Information Legend 308 
Supplementary material 1. The 23 key studies were selected from 75 studies relevant to GA-ONFH by the 309 
review of task force team. 310 
